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T cell immunotherapy is emerging as a powerful strat-
egy to treat cancer, and may offer new opportunities to
improve outcomes for patients with glioblastoma
(GBM). Our group has developed a chimeric antigen
receptor (CAR) T cell immunotherapy for GBM target-
ing IL-13 receptor a2 (IL13Ra2), a cell surface receptor
over-expressed by the majority of high-grade gliomas.
Towards this end, we have optimized IL13Ra2-specific
CAR T cells by incorporating enhancements in CAR
design and T cell engineering to improve T cell persis-
tence and antitumor potency. These include a second-
generation CAR containing the 41BB (CD137) costimu-
latory signaling domain (IL13BBζ-CAR), and a manufac-
turing strategy using an enriched central memory T cell
(TCM) population for genetic engineering. To model
clinical conditions and translate this therapy to patients
we used orthotopic human GBM models with low-pas-
sage patient-derived tumor sphere (TS) lines in NSG
mice. We demonstrate here that single injections of
optimized IL13BBζ-CAR TCM results in significantly
improved antitumor activity and T cell persistence as
compared to the early-generation IL13Ra2-CAR T cells
that were themselves capable of mediating transient
anti-tumor activity in patients. Evaluating routes for
delivery, intravenous (i.v.) versus intracranial (i.c.), we
find that i.c. delivery of the therapeutic CAR T cells eli-
cits superior antitumor efficacy as compared to i.v.
administration, which in these studies provided no
apparent therapeutic benefit. We also explored the capa-
city of T cells to traffic within the brain parenchyma,
and using a multifocal disease model establish that CAR
T cells injected i.c. at one tumor site are able to traffic
to a second tumor site in the contralateral hemisphere.
Further, we investigated variations in cell product com-
position, including CD4 to CD8 ratios, and observed
greater tumor recurrence in mice that received 100%
CD8+ CAR T cells, indicating that inclusion of CD4+
CAR T cell subsets improves the durability of the thera-
peutic response. Finally, we evaluated the impact of corti-
costeroid, given its frequent use in clinical management
of GBM, and demonstrate that low dose dexamethasone
does not diminish T cell antitumor activity in vivo. These
findings refine both CAR T cell product and clinical
parameters for optimally translating this therapy to
patients, and provide the rational for our newly initiated
first-in-human phase I clinical trial evaluating intracra-
nial administration of IL13Ra2-specific CD4+ CD8+
IL13BBζ-CAR TCM for the treatment of GBM.
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